Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Top 3 Hep C Studies for Primary Care
Highlights of 3 studies from 2017 that support the role of PCPs in HCV infection treatment, including prescribing direct-acting antiviral agents.
Three recent studies show the value of using direct-acting antiviral (DAA) agents to treat patients infected with hepatitis C virus (HCV), including treatment by primary care physicians:Â The majority of patients infected with HCV can be safely, effectively managed in a primary care setting.HCV viral load after four weeks of treatment with DAAs predicts sustained virologic response (SVR) in a real-world clinical setting.DAA therapy with sofosbuvir-based combinations safely and effectively treats HCV infection in patients with early-stage chronic kidney diseaseÂ
